As well as improving the health of asthma sufferers through more
effective and accurate monitoring, the trialled solution has the
potential to save time for hard-pressed GPs.  There will also be a saving in health service costs if there is a reduction in the incidence of critical cases requiring hospitalisation.  The analysis of the data could in
the future potentially contribute considerable value for the
pharmaceutical industry in terms of trend and statistical analysis and presentation for clinical trials.  